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Summary 
In applied research hypothetical information about the parameters in a 
stochastic model sometimes can be generated from theory or previous studies. 
Replacing unknown parameters by constants might increase the estimation 
accuracy. This is especially apparent when replacing parameters in non-linear 
expressions. The problem is how to handle the uncertainty of the hypothetical 
information. Here, a pretest procedure will be examined for an unknown 
exponent of the explanatory variable in a simple non-linear mixed model. The 
optimal pretest sizes for some parameter settings are found for a minimax 
regret criterion based on Mean-Squared-Error. The optimal test sizes were 
found to be approximately valid also for the case where no subject specific 
components are present. The examined class of models is useful for modelling 
concentration-time data for drugs with rapid absorption, and a small-sample 
example is given to illustrate the potential gain in estimation accuracy of the 
pretest approach in pharmacokinetics. 
Keywords: HIV; Longitudinal; Monoexponential; Pharmacokinetics; 
Preliminary test; Random coefficient regression; Small sample. 
1. Introduction 
Repeated measurements on subjects over time are collected in many research 
areas, and the information is then summarized for different purposes. In e.g. 
bioequivalence studies of drugs, measurements such as area under curve 
(AVe) and concentration decline rate are estimated from repeated 
concentration-time data on individuals. I, 2 The proposed systematic relationship 
between the outcome and the explanatory variables might be non-linear due to 
unknown parameters.3,4 A disadvantage when estimating in non-linear models 
is the need to use either analytical approximations or numeric techniques. The 
knowledge about the exact properties of these techniques is limited and they 
are associated with practical drawbacks such as convergence problems. 
Enabling the use of well-known and possibly more efficient estimators by 
restricting the model to a given linear relationship in its unknown parameters 
might be valuable. 
A linear model can be obtained if exact information about the parameters 
causing the non-linearity is incorporated. In reality only uncertain information 
about these parameters might be available, and the use of incorrect information 
can cause misleading results. However, if there is a large difference in 
efficiency of the estimators, the use of also slightly incorrect information can 
still be motivated to obtain larger estimation accuracy. The problem is then 
how to handle the uncertainty of the information. 
In this paper a pretest procedure which incorporates hypothetical information 
into the model estimation will be studied. Typically, a pretest procedure 
consists of a preliminary test on a specific parameter. The null-hypothesis can 
be generated from theory and an earlier research process, while the alternative 
hypothesis is based on the current sample. If the null-hypothesis is not rejected, 
the other parameters are estimated under the null-hypothesis. The pretest size 
can be optimised for certain criteria. 
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Pretesting has a long history5. 6 and has been extensively discussed in Judge and 
Bock7. In regression, estimation of a conditional mean after a pretest for 
pooling two independent samples has been studied by Bhoj et al8 for example. 
If the poolability was rejected, the estimator of the mean was based on only one 
of the samples. In an example a large potential to improve the estimation 
accuracy in terms of reduced Mean-Squared-Error (MSE) was found for the 
pretest estimator compared to the one-sample estimator. 
Here, the aim is to improve the estimation accuracy of the population 
parameters in a simple mixed model setting with an unknown parameter in a 
non-linear expression. Uncertain hypothetical information about the parameter 
will be incorporated using a pretest procedure. To the author's knowledge this 
has not previously been done for non-linear mixed models. In a related work9 
the significance of the quadratic term in a polynomial model of order two was 
tested as a preliminary test for non-linearity. However, this is a different test 
situation and the generalisation to longitudinal models was not treated. 
In the next section, the model is described in detail and motivated by examples. 
The model is simple in the way that there is only one explanatory variable, and 
non-linear in the sense that the explanatory variable has an unknown exponent 
p. This model is chosen for simplicity to illustrate the potential of pretest 
procedures, but is useful for mono-exponential relationships between the 
measured response and the explanatory variable. In Section 3 the estimators of 
the linear model (p known) and the non-linear model (p unknown) are 
described. The variances of the corresponding estimators are compared over 
different values of p. Motivated by the differences in variance, a pretest 
procedure is introduced in Section 4 and the minimax regret optimal pretest 
sizes are found for some small-sample parameter settings. The relation to the 
case when no subject specific components are present is examined. A brief 
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example of pretesting in pharmacokinetics is given. Section 5 is a concluding 
discussion. The estimators are defined in Appendix I, and the asymptotic 
variances of the estimators are given in Appendix II. 
2. The simple mixed model 
In order to keep the examination of the pretest as clear as possible, the study 
will be limited to a simple mixed model. The model allows for random 
intercepts over cross-sectional units but have a fixed slope: 
(1) 
where Yy is the response at ti for the j:th subject. The random intercept BOj 
reflects factors which are specific for the j:th subject, and the BOj 's and the 
eij 's are assumed to be independently and normally distributed. It then follows 
that the vector Yj = cr;r.~)' has a T-dimensional normal distribution. 
- - - I ' Further, let the expected value be ECYj I X)l'xI - XC Po I PI) and let the 
variance be where and 
- ( I ( ,) _ X = 1 i XI ••• Xi ••• xl' ) • The design is balanced in the sense that X is the 
1'x2 
same for all units. 
Longitudinal studies are common in research areas such as pharmacokinetics 
and pharmacodynamics. The expression expCYy) has a multiplicative structure 
according to (1) which is appropriate when the variability of the observed 
values increases with the size. This is a phenomenon frequently apparent in e.g. 
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human immunodeficiency virus (HIV) data10 and in concentration-time data4• 
Examples of curve shapes for different values of p are given in Figure 1. 
a. h. 
P=3 
Figure 1. Examples of curve shapes for different values of p; a.) Po + PI . t{ and h.) 
exp(Po + PI . t{) . 
The exp(Yy) -model has been used in HIV -studies. ll , 12 In such studies it is 
normally assumed that two infected cell compartments (productively infected 
cells and long-lived infected cells) can be identified based on plasma viral load 
data. Each of these two compartments is believed to produce a viral decay 
during treatment with potent antiviral therapies which can be modeled similar 
to exp(Yy). f31 is then the decay rate for the compartment, and it has been 
suggested that the decay rate reflects the potency (efficacy) of the antiviral 
therapies.13 Accurate estimation of the decay rates is thus important in 
bioequivalence studies of different regimens.14 
Further, in pharmacokinetics models similar to exp(Yy) have been suggested 
for concentration-time studies. In e.g. Davidian and Giltinan15 Chap 5.2.4 the 
model was used over each of the two apparent monoexponential phases of 
plasma concentrations following intravenous injection of indomethacin. The 
model has also been suggested for modelling the total concentration-time 
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relationships for drugs where instantaneous distribution between plasma and 
tissues takes place. In Gibaldi and Perrier16 Chap. 1 examples of modelling 
concentration in plasma after an intravenous dose of prednisolone, and in 
serum and heart tissue after an oral dose of dipyridamole are given. The 
population AVC can be found by integrating the expected value of exp(Yy) 
over time (cf. Gibaldi and Perrier16 p. 14). Since exp(Yy) has a lognormal 
distribution longitudinal models which separate the between-subject variance 
from the within-subject variance are required when estimating the AVC. 
In the referred studies above a strong assumption of linearity was imposed 
when the exponent p was put to unity, i.e. t1 • Even if this value is well-
founded, it may be incorrect in a new study where the circumstances might 
have changed slightly. The common more flexible non-linear alternative, i.e. 
the use of a general real-valued exponent p estimated from the current data, 
was discussed early by Box and Tidwell1? for a monotonic model like (1). The 
latter model was recently motivated and further developed for applications in 
medicine and epidemiologyl8, 19. However, introducing an unknown p means 
that we have a model which is non-linear in its parameters, and that we have an 
extra parameter to estimate. The estimator of the latter model can thus be 
suspected to be less efficient. By introducing a pretest procedure for p we can 
combine the use of uncertain hypothetical information with a more data-
dependent flexible modeling when Ho is rejected. An example where the 
pretest procedure is used for accurate and reliable estimation in bioequivalence 
studies is given in Section 4.3. 
For a more detailed characterization of viral decay rates or drug concentrations 
in body more detailed models are needed. In such case the parameters in (1) are 
regarded as functions of underlying differential equations.3, IO For simplicity 
this kind of models is not treated here. 
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3. Relative efficiency of the estimators 
Different estimators of the unknown parameters in (1) have to be used for the 
linear and non-linear models, respectively. For the linear model (p known), 
the Maximum Likelihood (ML) estimators from Appendix IA can be used. 
These estimators are denoted with a single hat. For the non-linear model (p 
unknown) simultaneous ML estimators can be found by maximizing the 
likelihood directly.2o Having a balanced design it is easy to find the ML 
solution from the derivative of the likelihood function with respect to p, cf. 
Appendix IB. The estimators in the non-linear case are denoted with a double 
hat. 
It is the purpose of this section to examine the differences in variance of the 
corresponding estimators in the linear and non-linear cases, respectively. The 
size of the differences indicates the potential gain of using a pretest approach. 
The relative precision of the estimators of a parameter e is examined using the 
ratio R = V(B)/V(fJ). 
In the examples, the parameter settings were chosen by practical experience. 
The study was concentrated to the interval 0.5 ~ p ~ 3 which covers a wide 
range of curve shapes adequate for the applications in this paper, see Figure 1. 
The t; 's were chosen as equally spaced on the interval [1,10]. It should be 
noted that the sample design is important for the efficiency of the estimators. 
This has been studied specially for pretesting in linear regression21 and more 
generally also in non-linear regression22, but is not treated here. 
3.1 Asymptotic variances of the ML estimators 
The asymptotic variances and covariances (n large) of the ML estimators can 
be obtained from the expectations of the second order derivatives of the 
Likelihood in (2), cf. Appendix II. It can easily be seen that the asymptotic 
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variances for the linear and non-linear model differ, except for the estimators of 
0-;0 and o-~ which have the same variance in both cases. It can further be seen 
that the R-ratio for the estimators of /31 does not depend on the variances, 
while the R-ratios for /30 and the mean function E[Y;j] = /30 + /31Xj do depend 
on the quotient 0-;0 / o-~ but not on the absolute magnitude of the variances. 
Finally, from Appendix II it can be seen that none of the three ratios depend on 
n. 
However, to get an idea about the losses in efficiency, the actual R-ratios over 
p have to be calculated in an example. Here, three quotients of the variances 
were chosen, 0-;0/0-; = 0.5, 1.0 and 2.0, which are of the same order as the 
estimated quotient 8;0/8; = 1.98 from the example in Section 4.3. 
When calculating the R-ratios they were found to be markedly below unity for 
the estimators of /30 and /31. Considering the former, it can be seen from 
Figure 2a that R is an increasing function of p which starts at a small value 
but ends at a fairly large value. For the estimators of /31' the value of R was 
found to be small with a local maximum of 1.1.10-2 at p = 0.90 (cf. Figure 
2b). The large difference in variances of the /31 -estimators is quite remarkable. 
However, it is important to remember that many common functions such as the 
mean curve and the tolerance limits do not involve /30 and /31 separately. From 
Figure 2c it can be seen that the R-ratio for E[r;j] is fairly large for all values 
of p, and always larger than the corresponding R-ratios for /30 and /31' 
respectively. This means that the relative increase in variance in the non-linear 
case is smaller for the combined estimator than for the single estimators. This 
result is due to the fact that the two estimators compensate each other which 
results in a relatively large R-ratio for the combined estimator. For simplicity 
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only results for the first time point XI are given here. From Figure 2a and 2c it 
can also be seen that R is positively related with the quotient of the variances, 
i.e. a relatively smaller a; tends to decrease the difference in variance of the 
estimators. 
a. b. 
1.0 0.012 
0.8 0.010 
0.008 
0.6 
Series order: 0:: 0:: 0.006 
0.4 - Quotient 2.0 0.004 
- Quotient 1.0 
0.2 
- Quotient 0.5 0.002 
0.0 0.000 
0.5 1.0 1.5 2.0 2.5 3.0 0.5 1.0 1.5 2.0 2.5 3.0 
P P 
c. 
1.0 
-
0.8 
_. 
-
0.6 
0:: Series order: 
0.4 - Quotient 2.0 
- Quotient 1.0 
0.2 
- Quotient 0.5 
0.0 
0.5 1.0 1.5 2.0 2.5 3.0 
P 
Figure 2. The R-ratio in (2) when estimating a.) Po, b.) PI and c.) E[I;j] for the three 
quotients of a~ / a; where n = T = 10 . 
3.2 Small sample results 
The small-sample situation is important in many research areas such as 
pharmacokinetics where the sample sizes and the number of observations per 
subject often are limited in early phases due to practical and ethical 
considerations To verifY that the results for the asymptotic variances in Section 
3.1 are relevant also in the given small sample situation, a simulation study 
9 
(100.000 replicates) was perfonned for p=0.5,0.6, ... ,3.0. The numeric 
estimation procedure introduced in Appendix IB was confinned to give 
unbiased estimators, with estimated variances close to the asymptotic variances 
from Appendix II. In the non-linear case, the maximal relative differences in 
variance were found to be about 2% for the estimators of flo, fll and E[1';j]' 
respectively. The corresponding differences in the linear case were found to be 
less than O.l %. Thus, the results in Section 3.1 are assumed to be applicable in 
the given small sample situation. 
4. Incorporating uncertain hypothetical information in the estimation 
procedure 
In Section 3 it was found that the estimators ofthe non-linear model can have a 
considerably larger variance than the corresponding estimators of the linear 
model. The loss in efficiency was also found to depend on the value of p. In 
many situations no infonnation about p is available, and the less efficient 
estimators of the non-linear model have to be used. Methods for improving the 
estimation accuracy in such situations include shrinkage and penalized 
likelihoods which were covered in a recent review.23 However, in this paper 
situations where hypothetical infonnation about p is available are treated. The 
results in Section 3 then point out that it can be valuable to incorporate such 
infonnation facilitating the use of the efficient estimators ofthe linear model. 
A common way to incorporate hypothetical infonnation in general is to use 
Bayesian methods, and different aspects of this have been studied extensively 
in phannacokinetics24, 25. In the Bayesian approach we have prior beliefs about 
the distributions of the popUlation parameters, and we incorporate the new 
sample still using estimators of the non-linear model to obtain our posterior 
distributions. An example of the latter can be seen when modelling the viral 
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decay in a HIV studyl2, 26, but this is not the situation studied in this paper. 
Here, our aim is to find a more accurate estimation approach by using the 
estimators of the linear model when appropriate. When the beliefs about P is 
based on a previous sample the empirical Bayes approach can be used as an 
alternative where the estimates of the linear and the non-linear models are 
weighted.27 However, in this paper our hypothetical information is considered 
as generated from theory and a previous research process, and not from a single 
sample. 
Here, a frequentistic pretest approach will be used to incorporate the 
hypothetical information about p. First, a pretest estimator is introduced which 
is based on both the estimators of the linear model calculated given a 
hypothetical Po' and the estimators of the non-linear model. Second, since Po 
is not necessary equal to p an optimal test size is discussed in terms of the 
MSE of the estimator. This is a combined measure of variance and bias which 
captures the accuracy, or closeness, ofthe estimator. Last, the pretest estimator 
is examined using the suggested optimal test size in a concentration-time data 
example. 
4.1 The pretest approach 
Having a hypothetically value Po the null-hypothesis Ho: P = Po can be 
tested. A pretest estimator of a parameter e in model (1) can be defined as: 
ir ={~ if Ho is not rejected at test size a E [0,1] 
e otherwise 
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where the linear model under Ho is estimated given Po. Estimating e.g. Po the 
pretest estimator will be P; = Po when Ho is not rejected, and P; = Po 
otherwise. 
Let the mean squared error of ea be MSE(a) = E[ (ea - 8)2 J. Further, let the 
hypothesis error be d = Po / P which is equal to unity if Ho is true. Some 
general properties of MSE(a) then follows from Judge et al28 Chap. 3.3.1a-c 
which to some extent explain the results in the sequel: 
1. a = 0 and a = 1 correspond to estimating under Ho and HI' 
respectively. 
2. MSE(O) < MSE( a) when a > 0 and d = 1. 
3. MSE(a) ~ MSE(1) when a> 0 and d ~ ±oo, i.e. for large deviations 
from Ho. 
4. For 0 < a < 1 the MSE(a) first increases and obtains a maximum 
larger than MSE(l) and then monotonically decreases to MSE(1) as d 
diverges from unity. 
5. MSE(a) ~ min{MSE(O),MSE(1)} , i.e. the lower limit of MSE(a) will 
always be the MSE of the estimators of either the linear or the non-
linear models. 
The distribution of ea is complicated, and the MSE(a)-curves were here 
examined using simulations over a d-interval sufficiently large to catch the 
relevant information. Ho was rejected for large values of the pretest statistic 
-210gA where A is the ratio of the ML functions under Ho and HI' 
respectively. Using critical values from the chi-squared distribution with one 
degree of freedom the test was found to approximately hold the nominal test 
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size. Over all examined parameter settings in the sequel, the maximal 
difference was 8% of the nominal test size a . 
As an illustrative example, some MSE(a)'s for E[I;j] when p=1 and 
a~o/a;=0.05/0.10=0.5 are given in Figure 3. For d=l, i.e. Po=p=l, 
MSE(O) is smallest and MSE(l) is largest as expected. This was found to be 
true for all d on the interval [0.961;1.038], with the equality 
MSE(O) = MSE(l) at the end points. It can also be seen that MSE(a) for all 
a> 0 tend to be equal to MSE(l) already for relatively small deviations of d 
from unity. Note that the curves in Figure 3 are not fully symmetric. The 
general findings in Figure 3 are valid also for the other parameter settings in 
this paper. 
0.10 
0.09 
D 
0.08 D 
D 
D 
0.07 D 
0.06 
Series order at d=1 
- - - - - 0=1 
x 0=0.4 
A 0=0.2 
o 0=0.1 
D 0=0.01 
D --0=0 
D 
D 
0.05 +-----,-----,-----,-----.-----,----------, 
0.7 0.8 0.9 
Figure 3. MSE(a) for E[l';j] when p=l. 
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d 
1.1 1.2 1.3 
In Figure 3, P was equal to unity. However, from Figure 4a it can be seen that 
the value of d where MSE(O) = MSE(1) for E['y;j] is a decreasing function of 
P for d > 1. Approximately this gives the length of the d-interval where 
MSE(O) < MSE(a) for a> 0 which thus can be seen to be decreasing with 
larger values of P and to be very short for P ~ 2. This length has in a further 
simulation study been found not to be dependent on O"~ , but to be a decreasing 
o 
function of nand T and to be an increasing function of 0"; . This result is to 
some extent surprising since we know from Section 3 that the R-values are 
dependent on the quotient O"~o /0"; , i.e. both variances. 
4.2 Optimal pretest size 
There are several common optimality criteria for pretesting, see e.g. Judge and 
Bock? Chap. 3.3.3. Here, a minimax regret solution will be considered where 
the regret, as a function of d , is defined as 
REG(a)=MSE(a)-min{MSE(O),MSE(1)}.29 The minimax optimal value of 
a, say a', is the value which minimises the maximum possible regret; 
sup REG ( a') :s; sup REG ( a) for d E (-00, +00) and all a ~ O. This criterion is 
d d 
reasonable for many applications since it avoids large losses in estimation 
accuracy both when d is close to unity and when it diverges more. 
Considering a situation where Po might be well-founded from an extensive 
previous research it is obvious that e.g. a very risk adverse criterion that just 
minimises max(MSE) would be inappropriate. The solution for the latter 
criterion would be to use a' = 1, since max(MSE(I)):S; max(MSE(a)) over 
d E (-00, +00). This would be a relatively inefficient solution if we can assume 
that Po is close to p. 
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The maximum regret of E[r;j] can be seen in Figure 4b as a function of a . In 
this example the minimum of the maximum regret-function can be found 
approximately for a' = 0.17 . Using the minimax regret optimality criterion the 
value of a' is determined by the shape ofthe MSE-curves. For d = 1 the MSE-
values are solely determined by the differences in variance of the estimators, 
and estimators with small R-values (c£ Figure 2) will then have relatively large 
regrets. When d"* 1 the shape of the MSE-curves is more complicated since it 
also depends on the bias, and a' thus have to be examined in a simulation 
study. 
a. h. 
1.20 
1.15 
"C 1.10 
1.05 
x 
Xx 
1.00 +-_~_x..c;.x-,,-x .... x ~ ................................. 
0.5 1.0 1.5 2.0 2.5 3.0 
p 
0.03 
e 
~ 0.02 
E 
" .~ 0.01 
'" ::;: Xx x.x .. xxx.. • 
0.00 +-----,---~---r--___. 
0.0 0.1 0.2 0.3 0.4 
a 
Figure 4. In a.) the values of d where MSE(O) = MSE(I) over p for E[.Y;j] , and in 
b.) the maximum MSE regret over d as a function of a when p = 1 . 
The minimax regret solution a' was examined in a simulation study for a 
variety of practically relevant parameter settings. The results do not indicate 
that a' depends on o-~o and 0-:, but on n, T and p for which the values are 
given in Table 1. The dependences are expressed differently for the different 
parameters. From Table 1 the value of a' can be seen to be relatively large and 
stable for the estimator of E[r;j] over p. This can probably partly be 
explained by the corresponding relatively large and stable value of R in Figure 
2c. Compared to E[r;j] we can see that a' for Po and PI is smaller for small 
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values of p, and approximately the same for larger values of p. From Figure 
2a-b we can then see that the explanation of the results in Table 1 is more 
complicated than only the differences in variance. Extreme parameter values 
were not treated here, but n = 5, T = 100 and n = 100, T = 5 were included for 
comparing a' in pre-clinical and clinical study settings, respectively. 
However, for the cases studied here no differences regarding a' were found. 
This is interesting since the values of nand T affect both the MSE's and 
variance and bias of the estimators to different extent. The main conclusion 
from Table 1 is that the level of a' is rather stable for the different settings and 
that it is relatively large compared to the nominal test sizes normally chosen in 
ordinary test situations. 
Table 1. Minimax regret optimal test sizes a' found in a simulation study. 
a' for 
p n,T a' for /30 a' for /31 E[~j] 
0.5 n=T=5 0.10 0.09 0.18 
n=T=10 0.14 0.13 0.18 
n=lOO, T=5 0.16 0.16 0.19 
n =5, T =100 0.16 0.16 0.19 
1.0 n=T=5 0.16 0.15 0.17 
n=T=10 0.15 0.15 0.17 
n =100, T =5 0.16 0.16 0.19 
n = 5, T = 100 0.16 0.16 0.19 
2:2.0 n=T=5 0.17 0.17 0.17 
n=T=lO 0.17 0.17 0.17 
n=lOO, T=5 0.17 0.17 0.19 
n =5, T =100 0.17 0.17 0.19 
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Having a balanced design, the estimation of the population parameters in mixed 
models is related to the case when no subject specific components are present, 
especially for a;o = o. This relation was first indicated in Section 3 where it 
was found that the R-ratio for PI does not depend on the variances, while the 
R-ratios for Po and E[Yij] depend on only the quotient a;j a; . In Table 1 a 
stronger indication of the relation was found since the results were found not to 
be dependent on the variances at all. The generalizability of the results in Table 
1 was further revealed in a study where a~ was put to zero. Approximately 
o 
the same results as in Table 1 were obtained also in this particular situation. 
4.3 An example of pretesting in pharmacokinetics 
To illustrate the potential gain of using a pretest procedure we will consider an 
early phase study of the pharmacokinetics of indomethacin following bolus 
intravenous injection of the same dose in 6 individuals.30 For each subject, 
plasma concentrations of indomethacin were measured at 11 time points 
ranging from 15 minutes to 8 hours post-injection. This data set was used by 
Davidian and Giltinanl5 in Chap. 5.2.4 where they represented each of the two 
apparent exponential phases of drug disposition by a mono-exponential 
function like exp(Yij). Here, the 5 observations equally spaced between 15 
minutes and 75 minutes are chosen as the first exponential phase for illustrative 
purposes. In Figure 5, the logarithm of the measured concentrations and the 
estimated mean functions E[Jij] for the linear model (where Po = 1 as in 
Davidian and Giltinan) and the non-linear model (p = 0.461) are shown. The 
sums of squares of errors for the two mean functions are relatively similar, 2.01 
and 1.90 respectively, which verifies that the chosen time interval is reasonable 
for representing the first phase. 
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Figure 5. E[r;j] for p = 0.461 (solid line) and Po = 1 (dashed line) and the logarithm 
ofthe concentrations in the example. 
The gain of using the suggested pretest procedure can be examined by 
comparing the MSE's for the linear and non-linear models, respectively, with 
the MSE of the pretest estimators using the minimax regret optimal test size. In 
a simulation study the parameter settings O"~ /0"; = 0.049/0.025 and 
o 
P = 0.461 were used as estimated from the data in Figure 5. Three different 
null-hypotheses were tested, Po = 0.461, 0.5, 1.0, where Po = 0.5 was 
included since it would be a natural ad-hoc value from looking at the data. The 
optimal test sizes were found in Table 1 for P = 0.5 . 
The results can be found in Table 2. For Po = P = 0.461 the results were 
expected from the results in Figure 2. The MSE(O) ' s from estimating Po and 
PI should then be much smaller than the corresponding MSE(a') 's and 
MSE(1) 's, while a smaller difference was expected when estimating E[r;j]' 
From the results in Figure 4a we know that the value of d can diverge 
relatively much from unity when P is small and still having the inequality 
MSE(O) < MSE( a) for a > O. In Table 2 this is clear regarding the results 
when Po = 0.5. MSE(O) is then still smallest, but the differences have 
decreased. For Po = 1 we can see that the power is almost 100% which gives 
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MSE( a') ~ MSE(1). However, all three MSE(O) ' s are now very large, even 
when estimating E[~j]. The decrease in MSE from the stabilizing effect of 
using a fixed Po is now erased by the bias ofthe estimators. 
Table 2. The ratio MSE( a) / MSE( a') where P = 0.461 . 
Estimated a' from Po = 0.461 Po =0.5 Po =1.0 
parameter: Table 1: a=1 a=O a=l a=O a=l a=O 
Po 0.10 1.63 0.062 1.19 0.18 1.00 5.88 
PI 0.09 1.66 0.024 1.20 0.16 1.00 6.60 
E[~j] 0.18 1.04 0.91 1.02 0.91 1.00 5.92 
The main conclusions from Table 2 are 1.) also incorporating relatively poor 
hypothetical information can decrease the MSE substantially compared to 
always estimating the non-linear model, and 2.) the risk in terms of MSE of 
using the linear model can be large also for reasonable choices of Po. 
However, it can be argued that the main interest is in the mean function for 
which the MSE only to a limited degree depends on the choice of model, and 
that the MSE's when estimating Po and PI separately are of less interest. This 
is partly true, since E[Yy] is important for calculating e.g. Aue in both 
pharmacokinetics and in pharmacodynamics.3) Nevertheless, also the single 
estimator of Po is important when e.g. adjusting the AUe for baseline.32, and 
PI is e.g. used for estimating viral decay rates32 and for shelf-life studies of 
drugs33• 
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5. Discussion 
It was the purpose of this paper to discuss accurate estimation strategies in non-
linear mixed models. To emphasise on the inferential issues of the pretest, the 
study was limited to a simple non-linear mixed model setting. First it was 
found that the relative difference in variance of the estimators of the linear 
model (p known) and the non-linear model (p unknown) can be considerably 
large. The difference is especially large for some estimators and some values of 
p. The problem was then how to utilize the efficient estimators of the linear 
model when p is unknown. Since uncertain hypothetical information about p 
might be available in e.g. bioequivalence studies, a pretest procedure based on 
both models was introduced. Optimal pretest sizes were found for a minimax 
regret criterion, and the benefits of the pretest approach were illustrated in a 
study of the pharmacokinetics of indomethacin. For d = 1 it was found that the 
MSE was decreased by up to 40% when using the pretest estimator instead of 
applying the non-linear model. The decrease was even larger, 85%, when 
comparing the pretest estimator to a reasonable linear model suggested in the 
literature. The suggested optimal pretest sizes were also found to be 
approximately valid for the case when no subject specific components are 
present. Having a balanced design this result was to some extent expected since 
the estimators of the longitudinal model then coincide, cf. Longford34 Chap. 
2.7. However, in Section 3 it was found that the difference in efficiency of 
some of the estimators depends on both 0";0 and 0";, which could have 
influenced the generalizabiIity. 
In Section 4 the linear model was tested versus the less restricted non-linear 
model. The assumptions about the restrictions are crucial for the subsequent 
inference. Here, Po was assumed to be generated from theory and an earlier 
research procedure and to be exogenous, i.e. independent of the stochastic 
variation in the present data sample. It should not be mixed up with 
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endogenous values from formal and informal modelling procedures. An 
example of the latter is when the value of Po is found by plotting and 
comparing the data with known functions (often from a limited ad hoc set as 
the square root, the linear, the quadratic and the cubic). Since this is a kind of 
pretesting in itself, the inference of the following formal pretest procedure will 
then be unclear. It should also be clarified that no absolute knowledge about p 
is assumed here, since it would then be inefficient to use pretesting. 
There are several optimality criteria7 of pretests and generally a relatively large 
test size is suggested. Three common criteria are: 1.) The minimax regret 
criterion which was used by Ohtanes when pretesting a linear hypothesis with 
the aim of estimating the residual variance. An optimal test size of about 30-
70% was then suggested. The minimax regret criterion was used in this paper 
due to its appealing minimisation of the maximal loss compared to using the 
optimal solution for given d. Compared to the two following criteria, this 
gives a solution which can be considered as more useful for situations where 
relatively accurate information about p might be available. 2.) Defining the 
relative accuracy as MSE(1)/ MSE(a) another criterion is to choose the test 
size that gives the maximum relative accuracy among the test sizes which 
guarantee at least a certain minimum relative accuracy over d . In Bhoj et al8 
and in Khan et al36 examples were given where the optimal test sizes were 
found to be 20% and 35% respectively. However, when using the single 
hypothesis pretest procedure in this paper it can easily be seen that the value of 
a' would then solely be determined by the subjectively chosen minimum 
relative accuracy. Both the sUbjectiveness and the fact that the optimisation is 
not at all based on the regret when d is close to unity can be questioned. 3.) A 
third criterion would be to minimize the average MSE(a), or equivalently the 
average regret, over d. 37 However, optimising over d E (-00,00) we will 
always chose a' = 1 since MSE(a) -+ MSE(1) when a> 0 and d -+ ±oo. This 
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is not a satisfactory solution in situations where Po is likely to be close to p, 
which can be expected in areas of extensive research. A pretest size of 100% is 
then inefficient since it does not enable the use ofthe efficient estimators of the 
linear model although the risk of a large MSE is small. 
In this paper only the properties of the pretest estimator has been examined. 
Another important issue is the inference of a main test following after a pretest. 
For example, the inference when testing the decay rates of two drugs after 
pretesting the exponent p will not be straight forward. As noted by 
Greenland38 in a discussion of reanalysis of epidemiologic databases using 
pretesting39, one has to construct confidence intervals and interpret tests results 
obtained from a likelihood function chosen by preliminary testing carefully. It 
has e.g. been shown that pretest estimators potentially have asymptotic non-
normality.40 
Further, it is well-known that the size of the main test may be inflated by the 
pretest procedure. This has been studied, e.g. for pretesting for non-linearity in 
regression followed by a main test for association between two variables, in 
Grambsch et ae. They found that the size of the main test increased by roughly 
50% and suggested simple modifications of standard practice to protect the size 
with only minimal loss of power. Pretest procedures are sometimes motivated 
by giving a larger power of the following main test. The difference in size and 
power between a test following after a pretest procedure and the test in the 
complete family has been studied by Albers et a141 • They used a preliminary 
test of equality of variances in two samples followed by a main test of the 
means. They found that the power change is often mainly nothing else but a 
factor times the size change. This implies that a larger power is only obtained if 
the size exceeds the nominal size. However, it has been shown that an 
increased sample size can reduce the consequences of pretesting with respect to 
size and power.42 
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Here, a class of simple non-linear regression models has been examined for a 
balanced design. A study of more general models including also other aspects 
of modelling such as prediction outside the study interval and tolerance 
intervals would be valuable. The study could also be extended to other 
parameters than the exponent and compared to the use of linearization 
procedures's. 
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Appendix I - The estimators 
Some denotations to be used below: 
n n n T 
Y=n-ILY; , Sw = L(Y; -Y/, Syy = LL(Y;j -Y;)2 , 
j=1 j=1 j=1 ;=1 
T TnT 
x= LX; IT, Sxx = L(X; _X)2 and Sxy = LL(x; -x)(Yy -Y;). 
;=1 ;=1 j=1 ;=1 
A. Estimators of the linear model. The estimators in the linear case, denoted by 
a single hat, are well-known and are given here for completeness. 43,44 Having a 
balanced design and a known p, the uniformly minimum variance unbiased 
estimators of the regression parameters in (1) are Po =! I.Po j and 
n j=1 
~ 1 n ~ ~ A 
PI = - " PI .. Here Po· and PI· are the ordinary least squares estimators of nf,:t } } } 
POj and Plj which are obtained by only using the data from the j:th subject. 
~2 A 
The variances are estimated as a~o = Sw _~ and a2 = Syy - PISxY 
n-l T n(T-I)-1 
It should be noted that the probability of a negative estimate of a~o lS 
p( a~o < 0) = p( F,,-I,n(T-Il-I < (1 + T· a~./ a;rl However, the properties of 
a~ are not examined in the paper. 
B. Estimators of the non-linear model. The ML estimators in the non-linear 
case are denoted by a double hat and are defined as the estimators in Appendix 
A 
IA but given the estimator p of p. To obtain p, start with the Likelihood of 
the observations in (1) 45: 
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(2) 
Recall that x; = t{ . The estimator p is then obtained by solving the equation 
510gL 5 () . 
---=- 2/31Sxy -/312Sxx =0 where the unknown A parameter IS 
5p 5p 
simultaneously replaced by its estimator. The resulting expression can be 
written as 
5L 
5p 
n T 
"''''Yx -nT·f·x L.L. 1) 1 
j=1 ;=1 
T 
'" 2 T-2 L.X; - ·X 
;=1 
n T T 
LLYijx; lnt; -nfLx; lnt; 
j=1 ;;1 T ;=1 = O. (3) 
Lx;2Int; -xLx; lnt; 
;=1 
In the simulation studies, Section 3.2 and 4, this approach was found to be very 
time-efficient when using a numeric grid search procedure over p in (3). 
Appendix II - The asymptotic variances 
The asymptotic variances and covariances (n large) of the estimators in 
Appendix I can be derived from the expectations of the second order 
derivatives of the Likelihood in (2).45 For a given p, the following expressions 
for the estimators of the linear model were obtained ( T ~ 2 ): 
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~2 2 [( )( 2 2)2 4J V(~2)= 2CT: V(CTB ) = 2 T -1 CTB T + CTe + CTe , v , 
o n(T -1)T 0 e n(T -1) (4) 
while all covariances between (Po ,/31) and (a~ ,a;) are zero. o 
Further, for the estimators ofthe non-linear model the following expressions in 
(5) and (6) were obtained. First put: M = ~ :i:>; In t;, SI = :t x; In t; - T . M . x , 
T ;=1 ;=1 
(5) 
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and 
(6) 
A 
while the asymptotic variances of and a; are the same as the 
A A 
corresponding variances in (4), and all covariances between (Po, PI' ~) and 
(8~ ,8;) are zero. Finally, using the previous results the variance of the 
o 
estimated mean function was approximated (Taylor series) by 
A A 
+2x;[cov(Po,PI) + PI ·lnt· cov(Po,ft) + PIX; ·In t· COV(PI,ft)]. 
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